Galderma
Galderma is a pharmaceutical company specializing in the research, development and marketing of dermatological treatments and was formed in 1981 as a joint venture between Nestlé and L'Oréal.
GaldermaLymecyclineAdapalene/benzoyl peroxideCalmuridCetaphilÉcole de Biologie IndustrielleMethyl aminolevulinateMetronidazolePimecrolimusFluocinolone/hydroquinone/tretinoinList of pharmaceutical manufacturers in the United KingdomPhotocureL'OréalNestléCampaigns & GreyWCG (firm)EmamectinSophia AntipolisTick YesList of companies in Dallas/Ft.Worth
Galderma Italy Deploys Comprehensive Cegedim Relationship Management Cloud ... - MarketWatch (press release)
Posted by admin / Under Galderma
Galderma Italy Deploys Comprehensive Cegedim Relationship Management Cloud ... MarketWatch (press release) PARIS, May 14, 2012 (BUSINESS WIRE) -- Cegedim Relationship Management today announced that Galderma Italy has fully deployed the cloud-based, next generation Customer Relationship Management (CRM) solution, Mobile Intelligence for iPad(TM) for its ... |
Published on Monday 21st of May 2012 10:57:22 PM
Reply Submitted to Pliaglis FDA Complete Response Letter - MarketWatch (press release)
Posted by admin / Under Galderma
Reply Submitted to Pliaglis FDA Complete Response Letter MarketWatch (press release) Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology. On April 16, 2012, Galderma received the Complete Response Letter from the FDA that outlined additional information the ... |
Published on Monday 21st of May 2012 10:57:22 PM
Pliaglis receives positive opinion from the BfArM in the E.U. - MarketWatch (press release)
Posted by admin / Under Galderma
Pliaglis receives positive opinion from the BfArM in the E.U. MarketWatch (press release) Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma SA (Galderma), a global pharmaceutical company specialized in dermatology and the individual country licenses will be issued directly to Galderma. Pursuant to Nuvo's license ... |
Published on Monday 21st of May 2012 10:57:22 PM
Nuvo Research Announces 2012 First Quarter Results - MarketWatch (press release)
Posted by admin / Under Galderma
Nuvo Research Announces 2012 First Quarter Results MarketWatch (press release) In April, Pennsaid weekly prescriptions retreated from their first quarter peak which coincides with Voltaren Gel supply resumption; Galderma SA (Galderma) advised that they received a Complete Response Letter from the US Food and Drug Administration ... |
Published on Monday 21st of May 2012 10:57:22 PM
Epidemiology of rosacea described in United Kingdom - Medical Xpress
Posted by admin / Under Galderma
Epidemiology of rosacea described in United Kingdom Medical Xpress "Our findings suggest that smoking may substantially reduce the risk of developing rosacea, whereas alcohol consumption is associated with only a small increase in risk." One author disclosed financial ties to Galderma, which funded the study. |
Published on Monday 21st of May 2012 10:57:22 PM
Mayo Clinic Allegedly Presents Flawed Research on "Melanoma Outbreak"; It Just ... - SBWire (press release)
Posted by admin / Under Galderma
Mayo Clinic Allegedly Presents Flawed Research on "Melanoma Outbreak"; It Just ... SBWire (press release) Tanner's Rights points out that the Nestle and L'Oreal companies created a partnership company called "Galderma" in 1981 with the goal of being the world's leading dermatology products company, according to the Galderma.com website. |
Published on Monday 21st of May 2012 10:57:22 PM
NovaBay: Tomorrow's Staple In Antimicrobial Therapy? - Seeking Alpha
Posted by admin / Under Galderma
NovaBay: Tomorrow's Staple In Antimicrobial Therapy? Seeking Alpha To put this into context, one of the world's largest dermatology companies, Galderma SA, has partnered with NovaBay to develop NVC-422 for impetigo. We saw in our analysis that Galderma has actually committed $62 million to NovaBay in milestone ... |
Published on Monday 21st of May 2012 10:57:22 PM
Dermatological Drugs: World Market Prospects 2012-2022 - MarketWatch (press release)
Posted by admin / Under Galderma
Dermatological Drugs: World Market Prospects 2012-2022 MarketWatch (press release) Our report discusses GSK, Galderma, Amgen, Abbott, J&J and other pharmaceutical companies, assessing prospects of the industry and market. Many commercial opportunities in treating skin disorders remain, including increased revenues. |
Published on Monday 21st of May 2012 10:57:22 PM
Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa(TM) for ... - MarketWatch (press release)
Posted by admin / Under Galderma
Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa(TM) for ... MarketWatch (press release) Loceryl(R) is a registered trademark of Galderma. MycoVa(TM) was also the subject of two Phase 3, randomized, double-blind, vehicle controlled, multicenter, parallel group studies to assess the efficacy, safety, and tolerability of MycoVa(TM). |
Published on Monday 21st of May 2012 10:57:22 PM
NovaBay Pharmaceuticals Provides Q1 - 2012 Financial Results - MarketWatch (press release)
Posted by admin / Under Galderma
NovaBay Pharmaceuticals Provides Q1 - 2012 Financial Results MarketWatch (press release) This decrease in cash is anticipated as we begin preparing for our Phase 2b conjunctivitis trial, provide support for Galderma regarding the Phase 2b impetigo trial and continue our trial in UCBE. NovaBay's license and collaboration revenue for the ... |
Published on Monday 21st of May 2012 10:57:22 PM
Find news
Share this!